Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5527]

Adjuvant pembrolizumab in resected merkel cell carcinoma shows improved distant...

Dr Janice Mehnert - NYU Langone Health, New York, USA

Adjuvant pembrolizumab in resected merkel cell carcinoma shows improved distant metastasis-free survival ( Dr Janice Mehnert - NYU Langone Health, New York, USA )

Trastuzumab deruxtecan demonstrates advance in treatment for HER2-positive...

Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA

Trastuzumab deruxtecan demonstrates advance in treatment for HER2-positive gastric cancer ( Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA )

IO102-IO103 cancer vaccine plus pembrolizumab demonstrates PFS benefit in...

Dr Inge Marie Svane - Copenhagen University Hospital, Copenhagen Denmark

IO102-IO103 cancer vaccine plus pembrolizumab demonstrates PFS benefit in advanced melanoma ( Dr Inge Marie Svane - Copenhagen University Hospital, Copenhagen Denmark )

Zanzalintinib plus atezolizumab improves survival in refractory mCRC

Dr Anwaar Saeed - University of Pittsburgh, Pittsburgh, USA

$Zanzalintinib plus atezolizumab improves survival in refractory mCRC ( Dr Anwaar Saeed - University of Pittsburgh, Pittsburgh, USA )$

Osimertinib plus chemo improves survival across high-risk subgroups in EGFR...

Dr Pasi Janne - Dana-Farber Cancer Institute, Boston, USA

Osimertinib plus chemo improves survival across high-risk subgroups in EGFR-mutated aNSCLC ( Dr Pasi Janne - Dana-Farber Cancer Institute, Boston, USA )

Low-dose pembrolizumab plus neoadjuvant chemo option for TNBC in resource...

Dr Atul Batra - All India Institute Of Medical Sciences Delhi, New Delhi, India

Low-dose pembrolizumab plus neoadjuvant chemo option for TNBC in resource-constrained settings ( Dr Atul Batra - All India Institute Of Medical Sciences Delhi, New Delhi, India )

Domvanalimab, zimberelimab and FOLFOX shows durable survival in advanced HER2...

Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA

Domvanalimab, zimberelimab and FOLFOX shows durable survival in advanced HER2-negative GC/GEJC/EAC ( Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA )

Abemaciclib combined with endocrine therapy improves OS in high-risk HR+, HER2−...

Prof Stephen Johnston - The Royal Marsden, London, UK

Abemaciclib combined with endocrine therapy improves OS in high-risk HR+, HER2− early breast cancer ( Prof Stephen Johnston - The Royal Marsden, London, UK )

Avelumab maintenance after reduced chemotherapy cycles improves QoL without...

Dr Enrique Grande - MD Anderson Cancer Center Madrid, Madrid, Spain

Avelumab maintenance after reduced chemotherapy cycles improves QoL without sacrificing survival in aUC ( Dr Enrique Grande - MD Anderson Cancer Center Madrid, Madrid, Spain )

Durvalumab combined with FLOT improves survival in resectable gastric and GEJ...

Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA

Durvalumab combined with FLOT improves survival in resectable gastric and GEJ adenocarcinoma ( Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA )

MCED blood test demonstrates high specificity, strong predictive value, and...

Dr Nima Nabavizadeh - Oregon Health & Science University, Portland, USA

MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection ( Dr Nima Nabavizadeh - Oregon Health & Science University, Portland, USA )

Enhancing breast cancer care through AI and collaboration

Dr Gabrielle Speijer, Dr Fernando Suarez and Dr Tolga Ozmen

Enhancing breast cancer care through AI and collaboration ( Dr Gabrielle Speijer, Dr Fernando Suarez and Dr Tolga Ozmen )

More from ecancer